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A B S T R A C T
Objectives: To analyze the sequence of the region involved in the development of quinolone resistance of
the gyrA and parC genes in a series of Bartonella bacilliformis isolates recovered prior to the introduction
of quinolones, as well as one clinical isolate recovered in the 1970s, establishing the susceptibility levels
to nalidixic acid and ciproﬂoxacin.
Methods: Five B. bacilliformis were studied: four isolated before 1957, prior to the introduction of
quinolones in clinical practice. The remaining strain was isolated in 1977. A fragment of the gyrA and
parC genes was ampliﬁed and sequenced. Susceptibility to nalidixic acid and ciproﬂoxacin was
established by the E-test method.
Results: All the strains were resistant to nalidixic acid (minimum inhibitory concentration (MIC)
>256 mg/l). Three isolates presented decreased susceptibility to ciproﬂoxacin and two were highly
resistant (MIC >32 mg/l). All the strains presented an Ala at position 91 of GyrA and position 85 of ParC.
Conclusions: B. bacilliformis presents a constitutive resistance to quinolones, which may be related to the
presence of Ala at position 91 of GyrA and 85 of ParC. These results advise against the current clinical
guidelines recommending the use of ciproﬂoxacin to treat bartonellosis in some countries of the Andean
area.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Bartonella bacilliformis is the etiologic agent of Carrion’s disease
or bartonellosis. Human infection with this pathogenic bacterium
has only been reported in the Andean valleys of Peru and regions of
Ecuador and Colombia.1–7 The transmission of B. bacilliformis is by
a vector insect, the female sandﬂy of the genus Lutzomyia spp.8
Carrion’s disease has two distinct clinical phases. The early or
acute phase named ‘Oroya fever’, in which B. bacilliformis infect the
erythrocytes and produce a severe anemia and in which there is a
transient immunosuppression.8 The later or chronic phase is the
so-called ‘verruga peruana’ or ‘Peruvian warts’, which is char-
acterized by the development of nodular dermal eruptions.6§ The results of this studywere presented in part at the 18th European Congress of
Clinical Microbiology and Infectious Diseases, April 2008, Barcelona, Spain, and at
the XIII Congreso de la Sociedad Espan˜ola de Enfermedades Infecciosas y
Microbiologı´a Clı´nica, May 2008, Madrid, Spain.
* Corresponding author. Tel.: +34 932 275400x2182; fax: +34 932 279853.
E-mail address: joruiz@clinic.ub.es (J. Ruiz).
1201-9712/$36.00 – see front matter  2009 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.07.025Moreover, B. bacilliformis may be isolated as a cause of asympto-
matic bacteremia.8
Prior to the antibiotic era, B. bacilliformis had the dubious honor
of being considered the bacteria leading to the highest levels of
mortality.8 The emergence of antibacterial agents in the early
1940s showed the high susceptibility levels that this microorgan-
ism presents, minimizing their impact.8
Different antibacterial agents have been used to treat B.
bacilliformis infections, such as erythromycin, chloramphenicol,
and rifampin, among others.9,10 Ciproﬂoxacin (Cip), which
possesses a good intracellular penetration and has been used to
treat infections due to other intracellular pathogens,11 has recently
been included as a ﬁrst-choice treatment in some areas such as
Peru.12,13
The administration of Cip for the treatment of acute and eruptive
bartonellosis has been described since 2001.7 Although treatment
with Cip has apparently been successful against infection by B.
bacilliformis,7,10 ofﬁcial reports from the Peruvian government have
described that after Cip treatment the patients seem to be fully
recovered, but 22.6% present chronic asymptomatic bacteremia.14ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Equivalence in the main amino acid position related to the acquisition of quinolone resistance
Microorganism GyrA ParC
Bartonella bacilliformis A-75 G-89 D-90a A-91 D-95a Q-111 G-83 D-84 A-85 D-89
Escherichia coli A-67b G-81b D-82b S-83 D-87 Q-106b G-78 D-79 S-80 D-84
a Positions at which substitutions related to resistance to ﬂuoroquinolones in mutants of B. bacilliformis obtained in vitro have been described to date.
b In E. coli, substitutions at these points have only been described in vitro.
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been reported.15
Different mechanisms of quinolone resistance have been
described, both chromosomal and plasmidic;16–19 however, the
most relevant at a clinical level are those related to the presence of
speciﬁc amino acid substitutions in the quinolone targets (DNA
gyrase, topoisomerase IV). At a clinical level the most frequent are
those raisedatGyrA(subunitAofDNAgyrase)andParC (subunitAof
topoisomerase IV).19 Among these, the substitutions at positions 83
and 87 ofGyrA and 80 and 84 of ParC in Escherichia coli, or analogous
positions in other microorganisms, are by far the most frequently
detected, while others have only been described in mutants
obtained in vitro, or in a few clinical isolates (Table 1).19 These
substitutions possess an additive effect. Thus, the presence of a
single substitution results in resistance to nalidixic acid (Nal), the
oldest quinolone,20 but only decreases the susceptibility to
ﬂuoroquinolones, requiring the presence of other substitutions to
develop full resistance to ﬂuoroquinolones. Additionally, the effects
on the quinolone resistance levels of each speciﬁc substitution are
not the same.19 It is of special relevance that the presence of
resistance toNal or decreased susceptibility to ﬂuoroquinolones has
beenrelated toanenhanced facility todevelop full resistanceagainst
these agents or to result in therapeutic failure.21–23
A report in 2003 showed the presence of an Ala as the wild-type
amino acid at position 91 of GyrA, equivalent to position 83 in
Escherichia coli (Table1).24Analysis of the completeDNAsequenceof
B. bacilliformis (GenBank accession number: NC 008783) showed
that the parC gene also encodes an Ala at position 85 (equivalent to
position 80 in E. coli). In the equivalent positions,wild-type E. coli, as
most other quinolone-susceptible microorganisms, presents Ser.19
Thus, it is of concern that thepresenceofAla at position83ofGyrA in
E. coli results inan increase in theminimuminhibitoryconcentration
(MIC) of Cip and in low levels of Nal resistance.25–27 This fact has
been related to the proposed mechanisms of interaction between
the quinolones and their targets.19 In this line, a recent study
designed to establish the interactions between different quinolones
and the GyrA of E. coli has demonstrated the presence of Van der
Waals contacts between Ser-83 and the substituent N1 of Cip.28
Following this lineof thought, othermicroorganisms thatpossess
an Ala at either or both of these two aforementioned positions, such
asBrucella spp,Brevundimonas diminutaor other species of the genus
Bartonella, are constitutively resistant toNal, or present resistanceor
diminished susceptibility levels to Cip (frequently with suscept-
ibility levels around 0.125–0.5mg/ml or higher).29–32 Moreover,
previous studies have shown isolates of B. bacilliformis with
decreased susceptibility to Cip (MIC around 0.25 mg/l) as well as
to other ﬂuoroquinolones.29,33Despite the lackof information onNal
resistance levels in B. bacilliformis in the literature, these data
strongly suggest that B. bacilliformis is constitutively resistant to Nal
and may possess naturally diminished susceptibility levels to other
moremodern ﬂuoroquinolones such as Cip, as has beenproposed by
Angelakis et al.32 Thus, the use of ﬂuoroquinolones as ﬁrst-line
treatment might not be recommended.
The main objective of the present study was to analyze the
sequence of the gyrA and parC genes, establishing the susceptibility
levels to Nal and Cip, in a series of B. bacilliformis isolates recovered
prior to the introduction of quinolones in clinical practice,30,34 as
well as one clinical isolate recovered in the 1970s.2. Materials and methods
2.1. Strains
We studied four B. bacilliformis isolates recovered between
1941 and 1957, as well as another recovered in 1977, acquired
from the collection of the Institut Pasteur, Paris, France (Table 2).
The microorganisms were recovered from freeze-dried stocks and
the identity was also conﬁrmed by PCR ampliﬁcation and
sequencing (BigDye Terminator v. 3.1 Cycle Sequencing Kit,
Applied Biosystems, Foster City, CA, USA) of the 16S rRNA gene
as previously described.35
In all cases, the microorganisms were grown on 5% blood agar
plates that were incubated at 28 8C in a 5% CO2 atmosphere and
controlled once a day in order to avoid contamination.
2.2. Extraction of DNA
The cells were collected from the plates, washed three times
with buffer phosphate and centrifuged at 13 000 g for 2 min. The
genomic DNA was then extracted using the Wizard1 Genomic
Puriﬁcation Kit (Promega, Madison, WI, USA) following the
manufacturer’s instructions. An aliquot of the DNA was analyzed
in 1% agarose gel by electrophoresis to evidence the quality of the
puriﬁed DNA. The genomic DNA was stored at 20 8C until use.
2.3. Ampliﬁcation and sequence of the gyrA and parC genes
A fragment of 233 bp of the gyrA gene (from position 172 to
position 404) was ampliﬁed using the primers previously
described,24 while 349 bp of the parC gene (from position 190 to
position 539) were ampliﬁed using the following primers: F parC
50-TCTTATGCTAAGTGTGCACGGA-30 and R parC: 50-TACCAACAG-
CAATCCCTGAAGAA-30. In both cases the PCR program was: 94 8C
1 min, 55 8C 1 min; 72 8C 1 min; 35 cycles. Two different PCR
ampliﬁcations of both the gyrA and parC genes were sequenced in
order to avoid possible Taq-introduced errors. In all cases the PCR
products were sequenced on both strands.
2.4. Detection of transferable mechanisms of quinolone resistance
The presence of qnrA, qnrB, qnrS, aac(6’)Ib-cr and qepA genes
was sought by PCR, using the primers and conditions previously
described.16–18
2.5. Antimicrobial susceptibility
Susceptibility to Nal and Cip was established by the E-test
method (AB Biodisk, So¨lna, Sweden) following the manufacturer’s
instructions. In all cases the plates were incubated at 28 8C in a 5%
CO2 atmosphere and controlled once a day in order to avoid
contamination.
2.6. Analysis of the hydrophobicity patterns
The predicted hydrophobicity pattern of the region containing
amino acid 91 of GyrA of B. bacilliformis was determined using the
method of Kyte and Doolittle36 deﬁned in the ProtScale37 software
Table 2
Characteristics of the analyzed isolates
Strains Source Isolation year GyrA ParC Nalidixic acida Ciproﬂoxacina
91 95 85 89 E-test E-test
GenBank Ala Asp Ala Asp
CIP 57.17 IP 1957 - - - - >256 0.25
CIP 57.18 IP 1949 - - - - >256 0.25
CIP 57.19 IP 1941 - - - - >256 >32
CIP 57.20 IP 1957 - - - - >256 0.125
CIP 77.27 IP 1977 - - - - >256 >32
IP, Institut Pasteur, Paris, France.
a Minimum inhibitory concentration in mg/l.
Figure 1. Predicted hydrophobicity pattern of the gyrA region that carries the
position 83 (Escherichia coli) and 91 (Bartonella bacilliformis). (A) Effect of the
substitutions of amino acid 83 in E. coli (Ser-wt; Ser to Ala; Ser to Leu). (B) Effect of
the substitutions of amino acid 91 in B. bacilliformis (Ala-wt; Ala to Ser; Ala to Leu).
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the complete sequence of GyrA of B. bacilliformis KC583 (accession
number: YP_989035). For comparison, the same region of the GyrA
of E. coli (accession number: YP 853338.1) was also included in the
analysis. In both cases the effect of the presence of Ser, Ala and Leu
on the hydrophobicity pattern was analyzed.
3. Results and discussion
All the isolateswere Nal-resistant, while in the case of Cip, three
of the isolates previous to the quinolone era presented a decreased
susceptibility, while the remaining isolates were highly resistant
(Table 2).
On analyzing the ampliﬁed regions of the gyrA and parC genes,
no changes with the B. bacilliformis sequences present in GenBank
were found (Table 2). Thus, an Ala was present at both position 91
of GyrA and position 85 of ParC. Additionally, none of the
transferable mechanisms of resistance searched was detected.
Three of the analyzed isolates presented susceptibility levels to
Cip of 0.125–0.25 mg/l, suggesting a poor interaction between Cip
and their targets, probably due to the presence of the aforemen-
tioned Ala at positions 91 of GyrA and 85 of ParC. The isolate CP
57.19 and the isolate CP 77.27 (recovered in 1977), presented aMIC
of Cip >32 mg/l, although neither a mutation in the analyzed
sequence of the gyrA or parC genes nor a transferablemechanismof
quinolone resistance was detected.
To our knowledge, only 21mutants obtained in vitro presenting
an increase in the Cip MIC with respect to the parental strain have
been investigated for the presence of amino acid substitutions in
GyrA.24,38 In ﬁve, the substitution Asp-95 to Asn (corresponding to
the substitution Asp-87 to Asn, a substitution frequently found in
quinolone-resistant isolates of E. coli) was detected, and in one the
substitution Asp-90 to Gly (corresponding to the substitution Asp-
82 to Gly, which has only rarely been described in resistant
mutants of E. coli obtained in vitro) was detected,19 while in the
remaining isolates, no substitutionwas detected in theGyrA region
analyzed, similar to the strains CP 57.19, and CP 77.27. It is possible
that these two isolates, as well as those mutants obtained by
Minnick et al.,24 present mutations outside the analyzed regions of
the gyrA and parC genes, or perhaps in the gyrB or parE genes, or
stable or unstable over-expression of efﬂux pumps able to pump
out quinolones.
On analyzing the predicted hydrophobicity patterns of this
region of GyrA, the results showed that the presence of an Ala at
position 91 results in increased hydrophobicity with respect to the
theoretical analysis of the presence of a Ser at these points.
Additionally, when we analyzed the presence of the same amino
acid substitutions in GyrA of E. coli, similar results were obtained.
Moreover, a higher increase was observed in the hydrophobicity
levels at this speciﬁc point when a Leu, the most frequent
substitution described in highly Cip-resistant mutants of E. coli, 19
was displayed at this position in GyrA. Finally, on comparing thehydrophobicity patterns of the wild-type amino acid sequences of
GyrA of both microorganisms, the hydrophobicity levels at the
aforementioned point was even higher in B. bacilliformis with
respect to E. coli (Figure 1). Similar results may be obtained on
analyzing the effect of analogous substitutions at position 85 of
ParC (data not shown). As has been previously mentioned,
quinolones interact with this position of GyrA (and probably with
that of ParC) by Van der Waals contacts, thus, alterations in the
hydrophobicity patterns, related to speciﬁc amino acid substitu-
tions at these points, might result in increased steric hindrance and
in associated increased levels of resistance (or in diminished
susceptibility).
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of resistance to ﬂuoroquinolones.21–23 Interestingly, in the only
study in which the in vitro frequency of a mutation of Cip in B.
bacilliformis was calculated,24 the results obtained were in the
same range as those obtained for Nal-resistant clinical isolates of E.
coli presenting a substitution in GyrA, and a minimum of 10-fold
higher than the frequency of mutations of wild-type E. coli.22 Thus,
the results obtained clearly show the risk of using ﬂuoroquinolones
to treat B. bacilliformis infections, and shows the need to analyze
the possible presence of therapeutic failure or relapse in the course
of Cip treatment.
This is a preliminary study, analyzing old isolates, designed to
validate the hypothesis of the intrinsic resistance of B. bacilliformis
to quinolones. Nonetheless, studies involving a large number of
isolates addressed to evaluate the susceptibility levels to
quinolones, including Nal, and establishing the presence of
possible substitutions in GyrA and ParC are necessary. However,
the fact that all the analyzed strains of B. bacilliformis recovered
prior to the introduction of quinolones presented an Ala, both at
position 91 of GyrA and position 85 of ParC (equivalent to positions
83 and 80 of the corresponding E. coli proteins), shows that this is
the original sequence of these genes, as has been introduced in
GenBank and reported by other authors.24,32 Thus, this sequence is
not due to the pressure exerted over this pathogen by the use of
quinolones.
Despite the small number of isolates analyzed, the data
presented here together with the lack of microbiological eradica-
tion of B. bacilliformis during Cip treatment,14 should discourage
the use of quinolones in the treatment of infections by B.
bacilliformis, in accordance with what has also been suggested
by other authors both for this and for other species of the genus
Bartonella.32,38
A surveillance of the current clinical situation is required in
order to evaluate the change in the current therapeutic schedules
in some Andean countries, such as Peru. Studies involving a larger
number of isolates, designed both to characterize the quinolone
targets and the susceptibility levels to Nal and to other more
modern ﬂuoroquinolones, are needed to establish it.
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